Our Pipeline
Tag: OBE022
Co‐administration of the prostaglandin F2α receptor antagonist pre‐term labour drug candidate OBE022 with magnesium sulfate, atosiban, nifedipine and betamethasone
Oliver Pohl, Line Marchand, Jean‐Pierre Gotteland, Simon Coates, Jörg Täubel, Ulrike Lorch
Safety and Pharmacokinetics of the Oral Prostaglandin F2alpha Receptor Antagonist, OBE022, in Patients With Threatened Spontaneous Preterm Labor
Andrew Humberstone, Jose Luis Bartha, Seppo Heinonen, Juha Räsänen, Aydin Tekay, Michel Brethous, Jean-Pierre Gotteland, Oliver Pohl, Ernest Loumaye
SRI Conference, 12-16 March 2019, Paris, France
Abstract S-001: page 299A
Abstracts. Reprod. Sci. 26, A62–A390 (2019). https://doi.org/10.1177/1933719119834079
Efficient Design of Integrated and Adaptively Interlinked Protocols for Early-Phase Drug Development Programs
Simon Coates, Oliver Pohl, Jean-Pierre Gotteland, Jörg Täubel, Ulrike Lorch
Article first published online: January 27, 2019
OBE022, an oral and selective prostaglandin F2α receptor antagonist as an effective and safe modality for the treatment of preterm labor
Pohl O, Chollet A, Kim SH, Riaposova L, Spezia F, Gervais F, Guillaume P, Lluel P, Meen M, Lemaux F, Terzidou V, Bennett PR, Gotteland JP.
Pharmacokinetics, safety and tolerability of OBE022, a selective prostaglandin F2α receptor antagonist tocolytic: A first-in-human trial in healthy postmenopausal women
Pohl O, Marchand L, Gotteland JP, Coates S, Täubel J, Lorch U
Effects of the Oral Prostaglandin F2 Alpha Receptor Antagonist Tocolytic OBE022 on Reproduction in Rats and Rabbits
Oliver Pohl, Roberta Sisti, Jean-Pierre Gotteland
SRI Conference, 06-10 March 2018, San Diego, CA
Abstract S-037: page 265A
Reproductive Sciences Vol. 25, Supplement 1, March 2018 265A Abstract S-037
Safety and Pharmacokinetics of the Oral Prostaglandin F2 Alpha Receptor Antagonist Tocolytic OBE022: A First-in-Human Study in Healthy Women
Oliver Pohl, Ulrike Lorch, Line Marchand, Jean-Pierre Gotteland
SRI Conference, 06-10 March 2018, San Diego, CA
Abstract S-038: Pages 265A-266A
Reproductive Sciences Vol. 25, Supplement 1, March 2018 265A-266A Abstract S-038
Confirmation of the Cardiac Safety of PGF2α Receptor Antagonist OBE022 in a First-in-Human Study in Healthy Subjects, Using Intensive ECG Assessments
Jörg Täubel, Ulrike Lorch, Simon Coates, Sara Fernandes, Paul Foley, Georg Ferber, Jean-Pierre Gotteland, Oliver Pohl
Confirmation of the Cardiac Safety of OBE022 in a First in Human Study in Healthy Subjects using Intensive ECG Assessments and the Effect of a Meal on QTc to Show Assay Sensitivity
J. Täubel, U. Lorch , G. Ferber , O Pohl
ACCP Conference, 17-19 September 2017, San Diego, CA
Poster 019: Page 16